With an exploding diabetic population in the world and the need for every diabetic patient to have their eyes screened at least once a year, the product is the solution to mass screen populations for the detection of diabetic retinopathy. Diabetic retinopathy affects 1 in 3 diabetics and 1 in 10 loses their vision because of this debilitating disease.
Early detection and intervention play a paramount role in the treatment of this condition. For resource-limited countries, where there are a limited number of human graders, the product can reduce the burden of screening exercises within an institution or country. The product can help ophthalmologists sieve through patients who need the treatment most.
The product can concurrently detect glaucoma and age related macular degeneration. The product is Singapore HSA approved and has recently attained CE Mark. The company is EN ISO13485:2016 accredited.
The company is actively looking for partners in Europe via distribution service agreement. Subject to discussion, the company is also open to other forms of collaborative efforts.